migraine: trends in treatment - oacns jackson-presen… · • migraine treatment has new...
TRANSCRIPT
4/4/2019
1
MIGRAINE:TRENDS IN
TREATMENTR H O N D A C O L E M A N - J A C K S O N D N P, A P R N - C N S
O U N E U R O L O G Y
A P R I L 1 2 , 2 0 1 9
LEARNING OBJECTIVESLEARNING OBJECTIVESLEARNING OBJECTIVESLEARNING OBJECTIVES
4/4/2019 2
By the end of the lecture, participants will be able to:
• Verbalize understanding of the role of Calcitonin Gene Related Peptide (CGRP) in migraine;
• Describe the mechanism of action for CGRP inhibitors, along with adverse reactions;
• Discuss other preventives and abortives in treatment of migraine;
• Identify neuromodulation treatment devices for migraine;
1
2
4/4/2019
2
TYPES OF MIGRAINE
• Episodic-at least 4-14 migraine days/month
• Chronic-over 14-16 migraine days/month
• Cluster
• Hemiplegic
• With and without aura
4/4/2019 3
TRIGEMINAL VASCULAR SYSTEM
� Activation of nociceptive trigeminal nerves by stimuli →
release of vasoactive peptides;
�Hyperemia followed by reduced cerebral blood flow is what happens with cortical spreading depression.
�20-40% reduction in cerebral blood flow spreads at 2-3 mm/min, which prevents the
ability for neurons to return to baseline
�Due to cytokine and neuropeptide involvement, inflammatory
processes are also implicated.
4/4/2019 4
3
4
4/4/2019
3
SEROTONIN 5HT RECEPTORS
4/4/2019 5
NEUROTRANSMITTERS
� Serotonin (5-HT)
�CGRP (calcitonin gene-related
peptide)
�Norepinephrine (NE)
�Histamine
�Substance P
�Nitric oxide (NO)
�Pituitary adenylate cyclase-
activating polypeptide (PACAP)
�Vasoactive intestinal peptide (VIP)
�Arachidonic acid metabolites
4/4/2019 6
5
6
4/4/2019
4
SEROTONIN
• 5 hydroxytryptamine (5-HT)
• Also involved in memory, mood, and sleep
• Migraine attack → increases serotonin acutely
�Increase CGRP, glutamate, NO release
�Increase in anxiety
�Increase in nausea (via 5-HT3)
�Increase GI motility (via 5-HT4)
4/4/2019 7
NEUROTRANSMITTERS
NOREPINEPHRINE
NE produced in the pons and influences thalamocortical projections
�NE prolongs activation of thalamic neurons
�Acts on alpha and Beta
�↑ in wakefulness and attention
SUBSTANCE P
• Acts as a potent vasodilator
• Triggers release of histamine from mast cells
• Likely contributes to neurogenic inflammation
4/4/2019 8
7
8
4/4/2019
5
HISTAMINE
• Produced in posterior hypothalamus � project to entire CNS
• Histamine receptors H1, H2, H3 expressed in CNS
�Excitatory for neurons, mostly via H1
�Histamine also contributes to vasodilation
• Migraineurs have ↑histamine levels ictally and interictally
�Sleep deprivation further ↑CSF histamine
4/4/2019 9
CGRPC A L C I T O N I N G E N E - R E L AT E D P E P T I D E
• Pronociceptive effects
� In inflammation and neurogenic pain, CGRP is upregulated
�Found in C and Aδ sensory fibers
• CGRP also acts as a potent arterial vasodilator
�Alpha (α) and beta (β)- CGRP receptors expressed in many body systems
� In cardiac disease, may serve a protective role
4/4/2019 10
9
10
4/4/2019
6
MIGRAINEPREVENTION
• Anti-Hypertensives
• Anti-Depressants
• Anti-Epileptics
• Botox
• CGRP Inhibitors
4/4/2019 11
ANTIANTIANTIANTI----HYPERTENSIVESHYPERTENSIVESHYPERTENSIVESHYPERTENSIVES
4/4/2019 12
Beta Blockers
• Poorly understood. Likely ↑ interictal serotonin levels through weak 5-HT antagonism.
• Inderal (Propranolol) Toprol (Metoprolol) Timolol, Tenormin (Atenolol) Corgard (Nadolol)
Calcium Channel Blockers
• Inhibits calcium ion influx into vascular smooth muscle
• Calan (Verapamil)
ACE Inhibitors
• (Prinivil) Lisinopril
Angiotensin Receptor Blockers (ARBs)
• Atacand (Candesartan)
11
12
4/4/2019
7
ANTI-DEPRESSANTS
Serotonin and Norepinephrine Uptake Inhibitors (SNRIs) �
� Effexor (Venlafaxine)-inhibits NE, serotonin,, and dopamine reuptake
� Cymbalta (Duloxetine)
Tricyclic Antidepressants �
� Elavil (Amitriptyline)-inhibits NE and serotonin reuptake
� Pamelor (Nortriptyline)
� Silenor (Doxepin)
4/4/2019 13
ANTI-EPILEPTICSMOA
• Topamax (Topiramate) → extended release products Trokendi XR or
Qudexy XR
• Depakote (Valproic Acid/Sodium)
• Neurontin (Gabapentin)
• Zonegran (Zonesimide)
4/4/2019 14
13
14
4/4/2019
8
OTHER PREVENTIVE MEDICATIONS
�Melatonin
�Magnesium
�B2 (Riboflavin)
�Namenda (Memantine)
4/4/2019 15
ONABOTULINUMTOXIN A (BOTOX) INJECTIONS
Administered for various treatments with multiple systems: antispasmodics (urinary) cosmetic (dermatologic) dystonia (Parkinson disease) migraine and ophthalmologic.
Mechanism of Action: inhibits acetylcholine release from nerve endings, reducing neuromuscular transmission and local muscle activity (neurotoxin).
• Up to 200 units every 12 weeks, usual dose is 155 units IM
• 31 injection sites
• Effects of botulinum toxin products may spread beyond treatment areas and produce muscle weakness, dysphagia, ptosis, and blurred vision.
4/4/2019 16
15
16
4/4/2019
9
SITES FOR BOTOX INJECTIONS
4/4/2019 17
Corrugator10 Units divided in 2 sites
Procerus5 Units in 1 site
Frontalis20 Units divided in 4 sites
Temporalis40 Units divided in 8 sites
Occipitalis30 Units divided in 6 sites
Trapezius30 units in 6 sites
MIGRAINE ABORTIVES• NSAIDs: Naproxen is the only medication that does not cause
medication overuse headache (MOH). Cambia is diclofenac powder that
is readily absorbed at onset of head pain (may cause MOH if used > 2
days per week.
• Triptans: Imitrex (Sumatriptan) Maxalt (Rizatriptan, Eletriptan,
Zolmitriptan)� cannot use if history of MI or stroke, due to
vasoconstriction. **Do not use > 2 days per week to avoid MOH**
• Anti-emetics: Vistaril (Hydroxyzine) Compazine (Prochlorperazine)
Phenergan (Promethazine)
• Dihydroergotamine (DHE-45) Do not use within 24 hours of a
triptan. Must be monitored as an inpatient prior to outpatient use.4/4/2019 18
17
18
4/4/2019
10
MIGRAINE ABORTIVES
Triptans
�Imitrex (Sumatriptan) oral, IM, nasal
�Maxalt (Rizatriptan) oral, oral disintegrating tablet
�Relpax (Eletriptan) oral
�Axert (Almotriptan) oral
�Frova (Frovatriptan) oral→ longer acting, used for menstrual
migraines
�Amerge (Naratriptan) oral
�Zomig (Zolmitriptan) oral, nasal spray
�Treximet (Naproxen/sumatriptan) oral4/4/2019 19
NON STEROIDAL ANTI INFLAMMATORY DRUGS
� Naproxen –ONLY NSAID that doesn't cause Medication Overuse
Headache (MOH)
� Indocin (Indomethacin)
� Cambia (Diclofenac Potassium)
4/4/2019 20
19
20
4/4/2019
11
ANTIEMETICS/ANTIHISTAMINES
�Phenergan (Promethazine)
� Compazine (Prochlorperazine)
�Vistaril, Atarax (Hydroxyzine)
� Periactin (Cyproheptadine)
4/4/2019 21
DIHYDROERGOTAMINE (DHE)
Dosing: 1 mg subcutaneous/IM/IV x 1. Max=3 mg/24 hours. May
repeat dose every 1 hour.
Black Box warning: life-threatening peripheral ischemia, ↑risk for
vasospasm leading to cerebral ischemia.
Contraindications: pregnancy/breastfeeding, renal or liver
impairment, coronary vasospasm, hemiplegic migraines.
Monitor CV periodically.
MOA: activates vascular serotonin 5-HT1D receptors, constricting
cranial and peripheral blood vessels.
4/4/2019 22
21
22
4/4/2019
12
OTHER TREATMENTS
• Thera Specs
• Migraine Cryohelmet
• Implanted pain pump
4/4/2019 23
ERENUMAB ((((AIMOVIGAIMOVIGAIMOVIGAIMOVIG))))
• Released in May 2018
• Blocks CGRP activity (monoclonal antibody) at the receptor
• Autoinjector
• Once per month injection
• 70 mg SQ or 140 mg SQ (70 mg x 2)→now available in one 140 mg
syringe
• Side effect: constipation
• $5 co-pay
4/4/2019 24
23
24
4/4/2019
13
GALCANEZUMAB (EMGALITY)
• Released in October 2018
• Blocks CGRP activity (monoclonal antibody)
• Auto-injector and pre-filled syringe
• Loading dose= 120 mg SQ x 2 initially, then 120 mg SQ monthly
• $0 co-pay
• Side effects: none
4/4/2019 25
FREMANEZUMAB ((((AJOVYAJOVYAJOVYAJOVY))))
• Released in October 2018
• Pre-filled syringe 225 mg/1.5 ml→ No autoinjector
• 225 mg SQ monthly or 225 mg x 3 every 3 months
• Same MOA as galcanezumab
• No side effects
• $0 co-pay card available for commercial insurers
4/4/2019 26
25
26
4/4/2019
14
GEPANTS
In the 2000’s caused liver toxicity-never approved by FDA
• Rimegepant
• Ubrogepant
• Atogepant
4/4/2019 27
DITANS
• Lasmiditan
• Phase III trials
• No vasoconstriction effects
• Take at onset of head pain
4/4/2019 28
27
28
4/4/2019
15
NEUROSTIMULATORS
• Cefaly®-prevent and abort
• gammaCore®-clusters and episodic
• eNeura®
4/4/2019 29
Cefaly
4/4/2019 30
29
30
4/4/2019
16
Cefaly Use• Non-drug, non-invasive migraine treatment;
• Used for migraine with and without aura;
• Acute treatment x 1 hour→ significant relief in 8 out of 10
patients;
• Preven%on→ 20 minutes daily → 54% reduc%on in migraine a*acks
• Side effects: allergy to electrode adhesive and inability to tolerate
sensation
• Contraindicated in those with metallic implants, pacemakers
• Covered by Flex Spending accounts
4/4/2019 31
gammaCore (nVNS)
• Non-invasive vagus nerve stimulator
• Use for prevention of cluster and episodic
• Avoids side effects of oral, injectable, or inhaled medications
• Co-pay assistance program
4/4/2019 32
31
32
4/4/2019
17
4/4/2019 33
e Neura device
• Non drug option for treating and prevention of migraine
• For adolescents (12 +) and adults
• sTMS mini (Transcranial magnetic stimulation)
4/4/2019 34
33
34
4/4/2019
18
SUMMARY
• Migraine treatment has new medications for prevention and
treatment with less adverse reactions.
• Many available preventives and abortives for migraineurs.
CGRP inhibitors are a safe alternative to daily oral medications.
• Patient assistance programs available.
• Neuromodulation devices available for prevention and treatment.
• Botox injections for chronic migraines > 16 episodes per month.
4/4/2019 35
REFERENCES:Bianca Raffaelli, Heike Israel, Lars Neeb & Uwe Reuter (2017) The safety and efficacy of the 5-HT
1F receptor agonist lasmiditan in the acute treatment of migraine, Expert Opinion on Pharmacotherapy, 18:13, 1409-1415, DOI: 10.1080/14656566.2017.1361406Matilde
Capi, Fernando de Andrés, Luana Lionetto, Giovanna Gentile, Fabiola Cipolla, Andrea Negro, Marina Borro, Paolo Martelletti & Martina Curto (2017) Lasmiditan for the treatment of migraine, Expert Opinion on Investigational Drugs, 26:2, 227-234, DOI: 10.1080/13543784.2017.1280457
Vila-Pueyo M. Targeted 5-HT1F Therapies for Migraine. Neurotherapeutics. 2018;15(2):291–303. doi:10.1007/s13311-018-0615-6
Lasmiditan is an effective acute treatment for migraine. Bernice Kuca, Stephen D. Silberstein, Linda Wietecha, Paul H. Berg, Gregory Dozier, Richard B. Lipton, on behalf of the COL MIG-301 Study Group Neurology Dec 2018, 91 (24) e2222-e2232; DOI: 10.1212/WNL.0000000000006641
4/4/2019 36
35
36